KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild type stage III colon cancers from an adjuvant chemotherapy trial (N0147 Alliance)

PURPOSE: We examined the prognostic impact of specific KRAS mutations in stage III colon adenocarcinoma patients receiving adjuvant FOLFOX alone or combined with cetuximab in a phase III trial (N0147). Analysis was restricted to BRAF-wild type tumors, since BRAF mutation was associated with poor pro...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Yoon, Harry H., Tougeron, David, Shi, Qian, Alberts, Steven R., Mahoney, Michelle R., Nelson, Garth D., Nair, Suresh G., Thibodeau, Stephen N., Goldberg, Richard M., Sargent, Daniel J., Sinicrope, Frank A.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2014
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4040326/
https://ncbi.nlm.nih.gov/pubmed/24687927
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-13-3140
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia